China’s regulators act fast after drug suspected in six patient deaths
Patient Safety Monitor: Global Edition, June 10, 2008
After previous promises to tighten up regulation of its pharmaceutical industry, Chinese regulators promptly reacted after six patients who received a blood-based drug at a Jiangxi province hospital, reports the International Herald Tribune.
All six patients were treated with the same batch of human immunoglobulin. Regulators swiftly made efforts to remove any remainders of the bad drug batch.
To read more, click here.
Comments
0 comments on “China’s regulators act fast after drug suspected in six patient deaths ”
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Answering service messages
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q&A: Coding for dry skin due to cold weather
- Q/A: Volume requirement for reporting hydration services
- Are your workforce members texting PHI?
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- Privacy, security concerns high in HIEs
- QA:Coding multiple initial infusions
- OB services: Coding inside and outside of the package
- E-mailed
-
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Volume requirement for reporting hydration services
- HIPAA Q&A: Level of encryption needed for email
- HIPAA Q&A: Answering service messages
- HIPAA Q&A: TPO disclosures to a business associate
- Are your workforce members texting PHI?
- Q&A: Coding for dry skin due to cold weather
- Hospitalist-surgeon comanagement has no effect on outcomes
- Don't let these sentinel events trigger falsely
- Correctly bill ancillary bedside procedures in addition to the room rate
- Searched
